Drs Eric Topol and Rob Califf discuss SCD-HeFT, PROVE-IT and SYNERGY.

SCD-HeFT also compared primary therapy with amiodarone with placebo; amiodarone had no effect on survival. The 2521-patient trial was conducted at 148 centers in North America and New Zealand.

The pain and impact of sickle cell disease (SCD) was associated with patient social and emotional functioning in a recent study.

Patients with severe sickle cell disease experienced significant quality of life improvements after receiving exagamglogene autotemcel gene therapy.